Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;49(3):220-230.
doi: 10.1111/cup.14130. Epub 2021 Sep 20.

Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms

Jeffrey D McBride  1   2 , John L McAfee  1 , Melissa Piliang  1   2 , Wilma F Bergfeld  1   2 , Anthony P Fernandez  1   2 , Shira Ronen  1 , Steven D Billings  1 , Jennifer S Ko  1
Affiliations

Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms

Jeffrey D McBride et al. J Cutan Pathol. 2022 Mar.

Abstract

Acral melanocytic neoplasms often pose diagnostic difficulty. Preferentially expressed antigen in melanoma (PRAME) expression and loss of p16 expression have diagnostic utility in melanocytic tumors. We examined PRAME and p16 expression in 30 acral melanocytic neoplasms (n = 11 nevi; n = 2 dysplastic nevi; n = 7 Spitz nevi; n = 10 acral melanomas). PRAME was scored as % positive nuclei: negative = 0%; 1% to 25% = 1+; 25% to 50% = 2+; 50% to 75% = 3+, or positive: 75% to 100% = 4+. p16 expression was defined as retained (homogeneous or checkerboard) or lost (complete or partial/regionally). PRAME expression was negative in all benign, dysplastic, and Spitz nevi. Conversely, all acral melanomas were diffusely (4+) positive for PRAME expression. p16 expression was retained in all benign acral nevi (8/11 homogeneous, 3/11 checkerboard), completely lost in one dysplastic nevus, and retained in all acral Spitz nevi (3/7 homogeneous, 4/7 checkerboard). p16 was retained in five of 10 acral melanomas (3/10 homogeneous; 2/10 checkerboard), and negative in five of 10 acral melanomas (absent in 3/10, partially lost in 2/10). Our data suggest that 4+ PRAME expression is highly sensitive and specific in the setting of acral melanomas and is a more predictive diagnostic tool compared with p16 immunohistochemistry.

Keywords: PRAME; Spitz; acral; immunohistochemistry; melanoma; nevus; p16.

PubMed Disclaimer

References

REFERENCES

    1. Teramoto Y, Keim U, Gesierich A, et al. Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. Br J Dermatol. 2018;178(2):443-451.
    1. Boyd AS, Rapini RP. Acral melanocytic neoplasms: a histologic analysis of 158 lesions. J Am Acad Dermatol. 1994;31(5):740-745.
    1. Darmawan CC, Jo G, Montenegro SE, et al. Early detection of acral melanoma: a review of clinical, dermoscopic, histopathologic, and molecular characteristics. J Am Acad Dermatol. 2019;81(3):805-812.
    1. Wiedemeyer K, Guadagno A, Davey J, Brenn T. Acral Spitz nevi: a clinicopathologic study of 50 cases with immunohistochemical analysis of P16 and P21 expression. Am J Surg Pathol. 2018;42(6):821-827.
    1. Ikeda H, Lethé B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6(2):199-208.

LinkOut - more resources